Cargando…
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor prognosis. This study aimed to identify potential therapeutic targets based on the expression profiles of differentially expressed genes (DEGs) in TNBC. METHODS: The Limma package w...
Autores principales: | Xu, Chao, Xie, Yongjie, Xie, Peng, Li, Jianming, Tong, Zhongsheng, Yang, Yanfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597932/ https://www.ncbi.nlm.nih.gov/pubmed/37875591 http://dx.doi.org/10.1007/s12672-023-00790-4 |
Ejemplares similares
-
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020) -
ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020) -
Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021) -
Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)